Analyst
Evercore
Equibles does not estimate personal net worth.
Umar Rafat is recorded as Analyst at Evercore. Umar Rafat has spoken on 8 earnings calls across 5 companies, most recently for Gilead Sciences, Inc. on May 7, 2026. Those appearances were for Gilead Sciences, Inc. (GILD), Viatris Inc (VTRS), Royalty Pharma plc (RPRX), ELI LILLY & Co (LLY) and Biogen Inc. (BIIB). The companies whose calls Umar Rafat spoke on are classified in the Healthcare sector.
“I was actually really looking forward to a possible update on your Phase 2 ulcerative colitis trial of the oral alpha 4 beta 7. I think CLIN trial says it wrapped up in March.”
“First, if you could just expand on the free cash flow year over year and what some of the drivers are.”
“I feel like there's been a good amount of discussion today on a lot of the effort Chris has been leading on R&D funding side.”
“I thought I'll spend a quick second on ZepBound's commercial dynamics in the U.S. And really what I'm trying to understand is, for example, 1Q, 7 million TRX, and 4.1 billion sales for ZepBound in the U.S., meaning it's about $580 per prescription.”
“First, on the cost cut announcement, the strategic review, could you break down for us the $650 million as it's broken down between COGS versus SG&A versus R&D?”
Evercore
Analyst
Transcript header (unverified)
Drug Manufacturers - General · Healthcare
VTRS
Drug Manufacturers - Specialty & Generic · Healthcare
RPRX
Biotechnology · Healthcare
LLY
Drug Manufacturers - General · Healthcare
BIIB
Drug Manufacturers - General · Healthcare
